Biotechnology - Biotechnology

Filter

Current filters:

Biotechnology

Popular Filters

201 to 225 of 2108 results

First Ph III Abraxane trial in metastatic pancreatic cancer to report three year survival rates

First Ph III Abraxane trial in metastatic pancreatic cancer to report three year survival rates

18-01-2014

US biotech firm Celgene’s breast cancer drug, Abraxane (nanoparticle albumin-bound paclitaxel), has…

AbraxaneBiotechnologyCelgeneOncologyResearchSpecialised Therapeutics Australia

MAb market for gastric and esophageal cancer expected to double by 2019

MAb market for gastric and esophageal cancer expected to double by 2019

18-01-2014

Due to favorable market conditions in terms of US pricing structures and the anticipated approval of…

BiotechnologyHerceptinMarkets & MarketingOncologyRoche

Nicox granted exclusive promotion and marketing rights for AMD test in North America

17-01-2014

French biotech firm NicOx SA (NYSE Euronext Paris: COX) and USA-based Sequenom (Nasdaq: SQNM) have entered…

BiotechnologyFranceLicensingNicOxOphthalmicsSequenomUSA

Shire sheds Dermagraft assets for $300 million in milestone payments

Shire sheds Dermagraft assets for $300 million in milestone payments

17-01-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has agreed to sell its Dermagraft (human fibroblast-derived…

BiotechnologyDermagraftDiabetesLicensingNorthern EuropeShire

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

17-01-2014

Belgian biotech firm ThromboGenics says that the Transparency Commission of the French National Health…

AlconBiotechnologyJetreaNovartisOphthalmicsPricingThromboGenics

Amgen and Illumina to develop companion diagnostic for Vectibix

Amgen and Illumina to develop companion diagnostic for Vectibix

16-01-2014

USA-based Illumina has entered into an agreement with Amgen to develop and commercialize a multigene,…

AmgenBiotechnologyIlluminaOncologyResearchVectibix

Amgen launches collaboration with academia for IBD drug development

15-01-2014

US biotech firm Amgen says it has launched a strategic collaboration with Massachusetts General Hospital…

AmgenBiotechnologyGastro-intestinalsMarkets & MarketingResearch

UK report on life sciences calls for greater freedoms for EU member states

UK report on life sciences calls for greater freedoms for EU member states

15-01-2014

A new UK report condemns the European Union’s “anti-biotech legislation” which is damaging Europe’s…

BiotechnologyEuropePoliticsRegulation

Surprise FDA advisory panel backing for Chelsea’s Northera

Surprise FDA advisory panel backing for Chelsea’s Northera

15-01-2014

A US Food and Drug Administration advisory panel has voted 16-one to recommend approval of US biotech…

BiotechnologyCardio-vascularChelsea TherapeuticsNorth AmericaNortheraRegulationUSA

Nektar’s etirinotecan pegol passes Ph III interim efficacy analysis

14-01-2014

US biotech firm Nektar Therapeutics says that the Independent Data Monitoring Committee created to provide…

BiotechnologyNektar TherapeuticsOncologyResearch

NantBioScience enters cancer collaboration with Celgene

NantBioScience enters cancer collaboration with Celgene

14-01-2014

USA-based NantBioScience, a subsidiary of privately-held NantWorks, has entered into a strategic collaboration…

AbraxaneBiotechnologyCelgeneLicensingNantBioSciencesNTB-010NTB-011OncologyResearch

Molecular nano-spies created to aid disease detection

Molecular nano-spies created to aid disease detection

14-01-2014

Stealth nano compounds have been designed by researchers at the UK’s University of Nottingham’s School…

BiotechnologyResearchUK

Agenus to acquire Switzerland’s 4-Antibody AG

14-01-2014

US biotech firm Agenus has entered into a definitive agreement to acquire 4-Antibody AG, a private Switzerland-headquartered…

4-Antibody AGAgenusBiotechnologyGITRMergers & AcquisitionsOncologyOX40

Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD

14-01-2014

US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…

BayerBiotechnologyEyleaLicensingOphthalmicsRegeneronResearch

GlaxoSmithKline returns Duchenne drug rights to Prosensa

GlaxoSmithKline returns Duchenne drug rights to Prosensa

13-01-2014

UK pharma giant GlaxoSmithKline says that its partner, Dutch biotech firm Prosensa has regained all rights…

BiotechnologydrisapersenGlaxoSmithKlineLicensingProsensaRare diseases

Cell Therapeutics to reacquire rights to two anti-cancer compounds

13-01-2014

US biotech firm Cell Therapeutics says it has reached an agreement with partner Novartis to reacquire…

BiotechnologyCell TherapeuticsLicensingNovartisOncologyOpaxioPixuvri

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

Regeneron amends investor agreement with Sanofi

Regeneron amends investor agreement with Sanofi

13-01-2014

US biotech firm Regeneron Pharmaceuticals says it has amended and restated its investor agreement with…

BiotechnologyMergers & AcquisitionsRegeneronSanofi

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer

13-01-2014

Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

Pharma M&A deals in 2013 down, but values marginally higher

Pharma M&A deals in 2013 down, but values marginally higher

13-01-2014

Merger and acquisition activity in the pharmaceutical, biotechnology and generic drugs sectors continued…

BiotechnologyGlobalMergers & AcquisitionsPharmaceutical

Alnylam to acquire Merck’s Sirna Therapeutics

Alnylam to acquire Merck’s Sirna Therapeutics

13-01-2014

US RNAi therapeutics specialist Alnylam Pharmaceuticals says it has reached agreement to acquire US pharma…

Alnylam PharmaceuticalsBiotechnologyMerck & CoMergers & AcquisitionsSirna Therapeutics

Mersana Therapeutics reaches second preclinical milestone in Endo collaboration

10-01-2014

Privately-held US biotech company Mersana Therapeutics has achieved its second preclinical milestone…

BiotechnologyEndo PharmaceuticalsFinancialLicensingMersanaOncologyResearchUSA

Nuevolution signs licensing agreement with Novartis

Nuevolution signs licensing agreement with Novartis

10-01-2014

Denmark-based Nuevolution has entered into a non-exclusive technology licensing agreement with Swiss…

BiotechnologyDenmarkGeneticsLicensingNorthern EuropeNovartisNuevolutionResearch

US drug approvals lower than previously reported; new study

10-01-2014

The overall success rate for drugs moving through clinical trials to US Food and Drug Administration…

BiotechnologyNorth AmericaPharmaceuticalRegulationResearchUSA

201 to 225 of 2108 results

Back to top